Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
Immunovant reported a fiscal first-quarter net loss of $153.2 million, or $0.75 per share, driven by a 41% increase in research and development expenses to $142.6 million to support ongoing clinical trials. The company ended the quarter with $797.8 million in cash and equivalents, stating this balance provides sufficient runway to the potential commercial launch of IMVT-1402 in Graves’ disease.
Key figures
- Net loss
- 153200000
- Ga expenses
- 17700000
- Rd expenses
- 142600000
- Cash balance
- 797800000
- Shares outstanding
- 206264878
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.